Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 29, 2007

Sanaria Awarded Grant to Fund Work on Malaria Vaccine

  • Sanaria received two multiyear SBIR grants from the NIAID to enhance the development of its whole parasite malaria vaccine.

    The phase II grant is to establish multiple strains of the parasite that can be used to assess the effectiveness of Sanaria's malaria vaccine. The phase I grant is to develop additional methods for preserving Sanaria's malaria vaccine.
    The total first-year award for both grants is $1.21 million. Subject to satisfactory progress by Sanaria, continued funding in the second and third year will bring the total to $3.47 million.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »